Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The AAV receptor (AAVR) is a cell-surface protein that serves as the primary point of entry for adeno-associated virus vectors in mammalian cells[2][5]. Engineering the interaction between AAV capsids and cell-surface receptors (AAVR or tissue-specific proteins such as integrins) enables selective and efficient gene delivery to neuromuscular tissue[4][3]. Strategies include overexpression of AAVR, capsid engineering to enhance receptor affinity, and development of AAV variants with tissue selectivity, which collectively improve transduction efficiency and the safety profile of gene therapy for diseases such as muscular dystrophies[3][4].
Enhanced tissue-specific gene transduction by engineered AAV capsids binding selectively to AAVR or muscle/tissue-enriched receptors
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AAV receptor (AAVR).